Journalists Unpack Latest on Vaccines, Vaping, and TrumpRx
KFF Health News journalists made the rounds on national media recently to discuss topical stories. Here’s a collection of their appearances.
Drug Costs
21-40 of 711 results
-
-
That Discount at the Pharmacy Counter May Pack Hidden Costs
The new TrumpRx program relies partly on connecting consumers with discount coupons offered by drugmakers. For insured patients, though, using a coupon can prove dicey.
-
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
By Elisabeth Rosenthal and Arthur Allen -
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
It may soon get easier for millions of people with Medicare to get discounted GLP-1 drugs for weight loss.
The Supreme Court Case That Could Slow Generic Drugs
Season 15, Episode 6In “Hikma v. Amarin,” the Supreme Court’s decision could affect how quickly generic versions of brand-name medicines come to market.
Abortion Pills, the Budget, and RFK Jr.
Episode 441This week, the Trump administration won a court battle to delay a ruling on access to the abortion pill mifepristone, angering its own anti-abortion allies. Meanwhile, the president’s budget arrived on Capitol Hill, where lawmakers are unlikely to agree to its proposed cuts to Health and Human Services programs. Lauren Weber of The Washington Post, Alice Miranda Ollstein of Politico, and Maya Goldman of Axios join KFF Health News’ Julie Rovner to discuss these stories and more.
New Flu Vax? FDA Says No Thanks
Episode 433It’s been a busy week at the FDA, with a political appointee overruling agency scientists to reject an application for a new flu vaccine. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Jackie Fortiér of KFF Health News, Lizzy Lawrence of Stat, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more.
Health Spending Is Moving in Congress
Episode 430Lawmakers appear on the brink of passing a spending bill for the Department of Health and Human Services and a bipartisan health policy bill delayed for over a year. But the outlook is bleaker for the health care outline released by President Trump last week. Sandhya Raman of CQ Roll Call, Sheryl Gay Stolberg of The New York Times, and Paige Winfield Cunningham of The Washington Post join KFF Health News’ Julie Rovner to discuss those stories and more. Also this week, Rovner interviews oncologist and bioethicist Ezekiel Emanuel to discuss his new book, “Eat Your Ice Cream.”
-
Medicaid Tries New Approach With Sickle Cell: Companies Get Paid Only if Costly Gene Therapies Work
The government is using sickle cell treatments to test a new strategy: paying only if the therapies benefit patients. With more expensive treatments on the horizon, the program — created by the Biden administration and continued under President Trump — could help Medicaid save money and treat more patients.
-
Millions of Americans Are Expected To Drop Their Affordable Care Act Plans. They’re Looking for a Plan B.
An estimated 4.8 million people are expected to go without health coverage because Congress did not extend enhanced subsidies for Affordable Care Act plans. But even without a health plan, people will need medical care in 2026. Many of them have been thinking through their plan B to maintain their health.
-
California Ends Medicaid Coverage of Weight Loss Drugs Despite TrumpRx Plan
Low-income Californians who use Wegovy and similar medications for weight loss lost their coverage at the start of the new year, with officials advising diet and exercise instead. California and other states say the drugs are too costly, even as the Trump administration announces plans to lower prices.
By Don Thompson -
The New Old Age
Older Americans Quit Weight Loss Drugs in Droves
In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side effects.
By Paula Span -
To Knock Down Health-System Hurdles Between You and HIV Prevention, Try These 6 Things
It’s been more than 10 years since the FDA first approved an HIV prevention drug. Today, people who could benefit from preexposure prophylaxis often struggle to access the lifesaving medicine or run into doctors without the education or empathy to offer affirming care. And those lapses can produce billing headaches.
By Zach Dyer -
FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office
Drug industry officials and analysts praised the FDA’s plans to streamline regulation of “biosimilars,” which are cheaper alternatives to biologic drugs. But patents that block such drugs from the U.S. market are getting harder to fight.
By Arthur Allen Schrödinger’s Government Shutdown
Episode 418Democrats and Republicans remain stalled over funding the federal government as Republicans launch a new attack on the Affordable Care Act. Meanwhile, the Trump administration is taking advantage of the shutdown to lay off workers from programs supported mostly by Democrats. Anna Edney of Bloomberg News, Lauren Weber of The Washington Post, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine join KFF Health News’ Julie Rovner to discuss those stories and more. Also this week, Rovner interviews health insurance analyst Louise Norris about Medicare open enrollment.
-
In Mississippi, Medicaid Coverage of Weight Loss Drugs Fails To Catch On
In Mississippi, a state with one of the highest obesity rates in the nation, Medicaid covers weight loss drugs, but few enrollees have signed up for the benefit.
-
Listen: Why ‘TrumpRx’ Might Not Save You Money
On the "Today, Explained" podcast, KFF Health News' Julie Rovner recaps the TrumpRx announcement and why the direct-to-consumer initiative may not save you money on prescription drugs if you have insurance through your employer or the government.
By Julie Rovner Democrats Make This Shutdown About the ACA
Episode 416The foreshadowed federal shutdown came after Congress failed to pass required spending bills, with Democrats demanding Republicans renew the expiring Affordable Care Act subsidies in exchange for their votes. While a shutdown does not affect Medicare and Medicaid, it could eventually hinder activities from every corner of the Department of Health and Human Services. Meanwhile, as Democrats and Republicans point fingers, HHS Secretary Robert F. Kennedy Jr. pursues policies and personnel that would undermine vaccines. Lauren Weber of The Washington Post, Shefali Luthra of The 19th, and Rachel Cohrs Zhang of Bloomberg News join KFF Health News’ Julie Rovner to discuss the news. Also this week, Rovner interviews KFF Health News’ Cara Anthony, who wrote a recent “Bill of the Month” feature about an out-of-network eye surgery that left one kindergartner’s family with a big bill.
Public Health Further Politicized Under the Threat of More Firings
Episode 415In a rambling news conference that shocked public health experts, President Donald Trump — without scientific evidence — blamed the over-the-counter drug acetaminophen, and too many childhood vaccines, for the increase in autism diagnoses in the U.S. That came days after a key immunization advisory panel, newly reconstituted with vaccine doubters, changed several long-standing recommendations. Former Centers for Disease Control and Prevention official Demetre Daskalakis joins KFF Health News’ Julie Rovner to discuss those stories. Meanwhile, Sandhya Raman of CQ Roll Call and Anna Edney of Bloomberg News join Rovner with the rest of the news, including a threat by the Trump administration to fire rather than furlough federal workers if Congress fails to fund the government beyond the Oct. 1 start of the new fiscal year.
-
As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off
Conventional wisdom says GLP-1 drugs must be taken indefinitely to maintain weight loss. But a growing number of researchers, payers, and providers are challenging that consensus and exploring whether — and how — to taper patients off expensive GLP-1 drugs.